# Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

> **NCT06017869** · PHASE2 · RECRUITING · sponsor: **Minovia Therapeutics Ltd.** · enrollment: 6 (estimated)

## Conditions studied

- Mitochondrial Diseases
- Pearson Syndrome

## Interventions

- **BIOLOGICAL:** MNV-201

## Key facts

- **NCT ID:** NCT06017869
- **Lead sponsor:** Minovia Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-31
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06017869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06017869, "Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06017869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*